Pandora's Box: The BZM Trilemma, Why Backlash Scales With Success Rather Than Failure, and Why Elpis Was Never Going to Diffuse

Hesiod's account, in Works and Days, gives Pandora a sealed pithos — a storage jar, not the box later tradition substitutes through Erasmus's mistranslation — containing every evil that would afflict mortal life. She opens it. The evils escape and cannot be recalled. One thing alone remains inside when the lid closes again: Elpis, a Greek term genuine classical scholarship still translates ambiguously between "hope" and "foreboding expectation." This paper argues the myth's two structural features — irrevocable release, and the selective trapping of exactly the thing that would make the release bearable — are not decorative parallels to this corpus's Biological Zero-Day Mechanism and its companion formalization, ALRP: The Floor That Does Not Rise. They are, read precisely against ALRP's own mathematics, the same structure. A BZM reset event is Pandora's hand on the lid: Δ(t), the gap between the discovery frontier F(t) and the diffusion floor D(t), jumps discretely and cannot jump back down — BZM's own Property 2, permanence, restated as a workload process no different in kind from the well-studied virtual-waiting-time object of a Poisson-arrival queue. What escapes immediately, on this reading, is the political consequence: this paper formalizes, using BZM's discreteness property and this corpus's own temporal-reclassification mechanism from They Who Remain, why a company's success at narrowing Δ(t) — not its failure — pulls more of the population from diffuse unawareness into the specific, attributable, newly visible margin just short of the frontier, a backlash-scales-with-success finding the informal case for a corporate "BZM trilemma" gestured at without deriving. What stays sealed inside the jar, on this same reading, is Elpis in its ordinary economic register: the standard diffusion-optimism narrative — prices fall, technology spreads, D(t) eventually reaches F(t) — which ALRP's own four-stage disaggregation shows cannot escape on any capital-responsive timeline, because the one stage that would need to accelerate to make the narrative true, clinical validation, is the single hard floor in the pipeline that no funding level moves. This paper further shows the trilemma the case study material proposes is not a true three-horned dilemma but a two-horned one — price high or price low — operating inside a wall neither horn can cross, and that the wall's immovability is not a policy failure but ALRP's own central finding restated at the scale of a single firm's actual choice set. The backlash-scales-with-success derivation is grounded, in addition, against three documented historical cases — the 1945 atomic bomb, 1990s antiretroviral access, and Merck's Keytruda patent strategy as reported by ICIJ's 2026 Cancer Calculus investigation — with the paper stating precisely why none of the three is a BZM case in this corpus's own technical sense even as each evidences the same underlying success-triggers-attribution mechanism. A closing section takes up Evo 2, this corpus's first confirmed BZM event outside longevity, and states directly where the myth's structure and BZM's actual structure diverge: Pandora's jar opens once; a publicly available 40-billion-parameter model that opened one box demonstrates the method by which the box can, in principle, be reopened independently by any actor clearing a roughly $200,000–$400,000 infrastructure threshold — a disanalogy this paper states rather than smooths over. A further section, added in this revision, extends the derivation to a second and structurally distinct mechanism: the reversible, ordinary reputational cost a company absorbs for a public forward promise not yet delivered — evidenced directly in Anthropic CEO Dario Amodei's August 2026 public statement that the industry has "not yet delivered on our big promises to benefit the world," naming the cure of cancer specifically as a promise now read as cliché rather than reassurance. This paper argues the reversible cost this statement documents, termed Phase 1, is not a risk parallel to the paper's original, permanent backlash-from-success mechanism, now termed Phase 2, but its forced predecessor: capital at the scale ALRP's own model requires is not committed without a prior public promise, making promise, Phase 1 exposure, and — conditional on success — conversion into Phase 2 a single forced sequence for any comparably resourced actor, with no silent exit available between them.